Free cash flow improved from -$103.1M in 2024Q1 to -$46.8M in 2026Q2 but remains deeply negative, with OCF/NI averaging 0.76 and cumulative net losses of -$534.5M outpacing operating cash burn of -$403.0M over ten quarters.
Zai Lab Limited (ZLAB) cash flow statement — 11-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 |
|---|
| Cash from Operations | -159.21M | -150.79M | -214.87M | -198.18M | -367.64M | -549.23M | -216.06M | -191.01M | -97.54M | -32.37M | -32.16M | -11.46M |
| Operating CF Margin % | - | -32.77% | -53.85% | -74.3% | -170.96% | -380.59% | -441.31% | -1471.04% | -75346.86% | - | - | - |
| Operating CF Growth % | -50.93% | 29.82% | -8.42% | 46.09% | 33.06% | -154.21% | -13.11% | -95.83% | -201.35% | -0.65% | -180.49% | - |
| Net Income | -198.39M | -175.54M | -257.1M | -334.62M | -443.29M | -704.47M | -268.9M | -195.07M | -139.07M | -50.38M | -37.51M | -18.02M |
| Depreciation & Amortization | 16.44M | 15.01M | 11.86M | 9.03M | 8.23M | 6.49M | 4.64M | 3.77M | 1.65M | 548K | 199K | 126.51K |
| Stock-Based Compensation | 52.37M | 65.6M | 70.65M | 79.63M | 61.3M | 40.71M | 24.83M | 20.29M | 12.23M | 9.93M | 4.93M | 2.7M |
| Deferred Taxes | -2.94M | 0 | 0 | 0 | 0 | 17.08M | 1.13M | 767K | 587.25K | 0 | 0 | 0 |
| Other Non-Cash Items | -21.03M | -1.15M | 28.12M | 8.17M | 72.36M | 67.85M | 4.01M | 2.52M | -312K | 62.74K | 1.92M | 2.02M |
| Working Capital Changes | -5.66M | -54.71M | -68.39M | 39.61M | -66.25M | 23.11M | 18.25M | -23.28M | 27.38M | 7.48M | -1.69M | 1.71M |
| Change in Receivables | 28.04M | -29.98M | -26.58M | -17.69M | 25.14M | -42.32M | -1.38M | -3.7M | -89.71K | 0 | 0 | 0 |
| Change in Inventory | -39.08M | -47.03M | 3.9M | -14.91M | -15.38M | -7.17M | -7.17M | -6M | -3.82K | 0 | 0 | 0 |
| Change in Payables | 17.14M | 19.93M | -2.21M | 36.8M | -53.77M | 63.52M | 39.98M | -14.77M | 28.46M | 8.44M | -929.72K | 1.29M |
| Cash from Investing | -47.68M | 307.87M | -375.19M | -10.78M | 420.02M | 249.96M | -554.83M | -14.89M | -212.55M | -10.43M | -2.73M | -738.47K |
| Capital Expenditures | -4.13M | -8.1M | -5.66M | -7.21M | -24.59M | -18.95M | -10.67M | -15.24M | -10.12M | -9.12M | -2.23M | -738.47K |
| CapEx % of Revenue | 0.93% | 1.76% | 1.42% | 2.7% | 11.43% | 13.13% | 21.79% | 117.38% | 7815.9% | - | - | - |
| Acquisitions | 0 | 0 | 29K | 0 | 0 | -30M | 539K | 9.21M | -2.09M | -1.9M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -43.55M | -5.24M | -55.86M | 12.74M | -399K | 3K | -539K | -9.21M | -102.83K | 68.1K | -505.62K | 0 |
| Cash from Financing | 37.9M | 72.35M | 349.89M | -6.43M | -1.73M | 820.2M | 1.13B | 219.3M | 144.15M | 187.86M | 106.2M | 18.28M |
| Debt Issued (Net) | 37.82M | 67.94M | 131.32M | 0 | 0 | 0 | -6.53M | 2.9M | 3.64M | 0 | 0 | 0 |
| Equity Issued (Net) | 4.78M | 13.68M | 217.35M | 0 | 0 | 818.88M | 1.14B | 216.2M | 141M | 189.53M | 106.2M | 18.28M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -4.7M | -9.27M | 1.22M | -6.43M | -1.73M | 1.33M | 1.28M | 201K | -496.2K | -1.67M | 0 | 0 |
| Net Change in Cash | -167.49M | 229.91M | -240.48M | -218.01M | 44.37M | 522.04M | 366.42M | 13.49M | -166.71M | 145.71M | 70.79M | 6.01M |
| Free Cash Flow | -163.96M | -164.21M | -276.39M | -206.67M | -392.63M | -568.18M | -226.72M | -206.25M | -107.66M | -41.48M | -34.39M | -12.2M |
| FCF Margin % | -37.12% | -35.69% | -69.27% | -77.49% | -182.58% | -393.72% | -463.1% | -1588.42% | -83162.76% | - | - | - |
| FCF Growth % | 20.72% | 40.59% | -33.74% | 47.36% | 30.9% | -150.6% | -9.93% | -91.59% | -159.51% | -20.64% | -181.79% | - |
| FCF per Share | -1.46 | -1.50 | -2.79 | -21.39 | -40.98 | -61.10 | -29.19 | -32.04 | -20.46 | -19.07 | -36.43 | -14.04 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.86x | 0.84x | 0.59x | 0.83x | 0.78x | 0.80x | 0.98x | 0.70x | 0.64x | 0.86x | 0.64x |
| Interest Paid | 454K | 4.88M | 2.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ZLAB stock.
Zai Lab Limited (ZLAB) generated $-150.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Zai Lab Limited (ZLAB) reported negative free cash flow of $164.2M in 2025, indicating capital requirements exceeded cash from operations.
Zai Lab Limited (ZLAB) spent $8.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating losses
Metrics are mathematically derived from official filings.
Cash Conversion Remains Elusive
Zai Lab's operating cash flow has consistently underperformed net losses, with OCF/NI averaging 0.76 over the past ten quarters, indicating persistent negative accruals and weak earnings quality.
The gap between net income and operating cash flow is stark: in 2026Q1, OCF was -$11.9M versus a net loss of -$51.0M, a ratio of 0.23, suggesting that non-cash charges like SBC and D&A are masking a deeper cash burn. However, in 2025Q1, OCF exceeded net loss (ratio 1.27), driven by a large working capital outflow, highlighting volatility in cash conversion. This inconsistency suggests that reported losses do not fully capture the cash drain, and investors should monitor the sustainability of working capital swings.
FCF Burn Persists Despite Narrowing
Free cash flow has improved from -$103.1M in 2024Q1 to -$46.8M in 2026Q2, but remains deeply negative, with FCF margins improving from -118.3% to -44.1% over the same period.
The trajectory shows a gradual narrowing of FCF burn, but the improvement is not linear; 2025Q1 saw a spike to -$65.6M, and 2026Q1 improved to -$34.2M before widening again. This suggests that cost controls are having some effect, but the company is still far from cash flow breakeven. Given the prior income statement analysis showing decelerating revenue growth, the FCF improvement may be driven by working capital timing rather than operational leverage, warranting caution.
Minimal Capex Signals Asset-Light Model
Capital expenditures have averaged just 1.4% of revenue over the past ten quarters, totaling roughly $16M, indicating a highly asset-light model with limited need for fixed asset investment.
With CapEx/Revenue consistently below 3%, Zai Lab's cash burn is almost entirely operational, not capital-intensive. This suggests that the company's investments are primarily in R&D and commercialization rather than physical assets, which may be typical for a biotech. However, the low capex also implies that future growth may require significant external funding for manufacturing or infrastructure, which is not yet reflected in the cash flow statement.
Working Capital Swings Drive Cash Volatility
Working capital changes have swung from -$57.2M in 2024Q1 to +$35.9M in 2026Q1, creating significant quarter-to-quarter volatility in operating cash flow, as reported in quarterly filings.
The working capital line is the primary driver of OCF volatility, with large outflows in 2024Q1, 2025Q1, and 2025Q3, and inflows in 2026Q1. This pattern suggests that Zai Lab's cash flow is heavily influenced by timing of receivables, payables, and inventory, which may not reflect underlying operational performance. Investors should monitor whether these swings indicate improving efficiency or simply timing mismatches, as the company continues to burn cash.
No Capital Returns, All Cash to Operations
Zai Lab has paid no dividends and repurchased only $2.2M in shares in 2026Q2, with no acquisition activity, indicating that all available cash is being consumed by operating losses.
The absence of dividends and minimal buybacks underscores that the company is in a preservation mode, with cash reserves being used to fund ongoing losses. The $2.2M buyback in 2026Q2 is negligible relative to the quarterly burn, suggesting it may be opportunistic rather than a strategic return of capital. This deployment strategy is consistent with a company that needs to conserve cash to extend its runway, but it also means shareholders are not receiving any direct returns.
Cumulative Losses Outpace Cash Burn
Over the past ten quarters, cumulative net losses totaled -$534.5M while operating cash flow was -$403.0M, a $131.5M divergence that suggests non-cash charges are inflating reported losses.
The cumulative gap between net income and operating cash flow indicates that a significant portion of reported losses are non-cash, primarily SBC and D&A, which totaled approximately $150M over the period. This divergence implies that the actual cash burn is lower than the accounting losses, but still substantial. However, the gap is not consistent, and the company's cash position may be deteriorating faster than the income statement suggests, given the working capital outflows. This warrants close monitoring of the balance sheet.
What Could Invalidate the Base Case
The cash flow statement may obscure the true cash position due to significant stock-based compensation and working capital timing, potentially understating the urgency of funding needs.
While SBC and D&A are non-cash, they represent real dilution and asset consumption that are not captured in operating cash flow. The large working capital swings could be masking a more stable underlying burn, and the absence of capex may understate future capital needs if the company scales manufacturing. Investors should consider that the reported cash burn may not fully reflect the economic cost of operations, and the company may need to raise capital sooner than the cash flow statement alone suggests.